title: Basiliximab decreases the incidence of acute rejection after intestinal transplantation.
authors.affiliation: University of Nebraska Medical Center, Nebraska Health Systems, Omaha, Nebraska 68198, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Sudan
authors.forename: S
authors.initials: S
authors.lastname: Chinnakotla
authors.forename: S
authors.initials: S
authors.lastname: Horslen
authors.forename: K
authors.initials: K
authors.lastname: Iyer
authors.forename: I
authors.initials: I
authors.lastname: Fox
authors.forename: B
authors.initials: B
authors.lastname: Shaw
authors.forename: A N
authors.initials: AN
authors.lastname: Langnas
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002675:Child, Preschool; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007223:Infant; D007239:Infections / Q000453:epidemiology; D007422:Intestines / Q000637:transplantation*; D016031:Liver Transplantation / Q000276:immunology; D011183:Postoperative Complications / Q000453:epidemiology; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab